CoChat
Sign Up
Cited by 259Inflammatory Bowel DiseaseSmoking Behavior and CessationMicroscopic Colitis

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Transdermal Nicotine for Mildly to Moderately Active Ulcerative Colitis: A Randomized, Double-Blind, Placebo-Controlled Trial

Sandborn, William J., Tremaine, William J., Offord, Kenneth P., Lawson, George M., Petersen, Bret T., Batts, Kenneth P., Croghan, Ivana T., Dale, Lowell C., Schroeder, Darrell R., Hurt, Richard D.·1997·Annals of Internal Medicine
DOI 10.7326/0003-4819-126-5-199703010-00004
Open this paper in CoChat — free account

Abstract

BACKGROUND: Ulcerative colitis is predominantly a disease of nonsmokers. Transdermal nicotine may help control clinical manifestations of this condition. OBJECTIVE: To determine the efficacy of transdermal nicotine for controlling clinical disease activity in active ulcerative colitis. DESIGN: Randomized, double-blind, placebo-controlled, single-center clinical trial. SETTING: Multispecialty group serving as an academic tertiary referral center. PATIENTS: 64 nonsmoking patients with mildly to moderately active ulcerative colitis despite the use of medication. INTERVENTION: Patients were stratified on the basis of smoking history, extent of disease, and concomitant medical therapy. After stratification, patients were randomly assigned to daily treatment with transdermal nicotine (n = 31) at the highest tolerated dose (11 mg for 1 week and then < or = 22 mg for 3 weeks) or placebo (n = 33). MEASUREMENTS: Clinical features were assessed at baseline and 4 weeks by endoscopy, physician assessment, and a patient diary of daily symptoms. Serum concentrations of nicotine were determined by using gas chromatography and mass spectrometry, and plasma concentrations of cotinine were measured by using high-performance liquid chromatography. RESULTS: At 4 weeks, 12 of 31 patients (39%) who received nicotine showed clinical improvement compared with 3 of 33 patients (9%) who received placebo (P = 0.007). Four patients receiving nicotine discontinued therapy because of side effects (contact dermatitis [n = 2], nausea [n = 1], and acute pancreatitis [n = 1]). At week 4, the nicotine group had a mean (+/-SD) trough serum nicotine concentration of 11.3 +/- 8.4 ng/mL and a mean trough plasma cotinine concentration of 192 +/- 95 ng/mL. CONCLUSIONS: Transdermal nicotine administered at the highest tolerated dosage (< or = 22 mg/d) for 4 weeks is efficacious for controlling clinical manifestations of mildly to moderately active ulcerative colitis.

Overview

Integrity signals

Registry

Crossref · 10.7326/0003-4819-126-5-199703010-00004

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 17 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Sandborn, W. J., Tremaine, W. J., Offord, K. P., Lawson, G. M., Petersen, B. T., Batts, K. P., Croghan, I. T., Dale, L. C., Schroeder, D. R., & Hurt, R. D.
Affiliations
Mayo Clinic (US)
Corresponding author
Sandborn, William J.
Venue
Annals of Internal Medicine
Publisher
American College of Physicians
Published
1997-03-01
Volume
126
Issue
5
Pages
364-371
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
DOI
10.7326/0003-4819-126-5-199703010-00004
OpenAlex
W1968829609
Cited by
259
References
17
Citations by year
2026: 2 · 2024: 8 · 2023: 7 · 2022: 4 · 2021: 3 · 2020: 9 · 2019: 5 · 2018: 4 · 2017: 7 · 2016: 3 · 2015: 3 · 2014: 7 · 2013: 8 · 2012: 6
FWCI
10.27
Type
journal article
Language
en
Open access
closed
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
Locations
  • Annals of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Annals of Internal Medicine
Topics
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
  • Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
Keywords
ulcerative colitis, transdermal nicotine, nicotine therapy, smoking cessation, non-smokers, disease activity, clinical improvement, plasma cotinine, adverse effects, contact dermatitis, acute pancreatitis
MeSH terms
Administration, Cutaneous, Adolescent, Adult, Aged, Colitis, Ulcerative, Cotinine, Dermatitis, Contact, Double-Blind Method, Female, Humans, Male, Middle Aged, Nausea, Nicotine, Placebos, Remission Induction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review